Welcome to our dedicated page for Genetron Holdings news (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings stock.
Genetron Holdings Limited (NASDAQ: GTH) is a leading precision oncology platform company based in China. With a focus on cancer molecular profiling, Genetron leverages advanced technologies in molecular biology and data science to revolutionize cancer treatment.
The company's extensive portfolio spans various stages of cancer management, including early screening, diagnosis, treatment recommendations, and continuous monitoring. Some of its flagship services and products include:
- HCCscreen: A proprietary assay for the early detection of liver cancer.
- 8-gene Lung Cancer Assay: An in-vitro diagnostic tool based on semiconductor sequencing for lung cancer detection.
- Genetron 3D Biochip Reading Instrument and Genetron S5 and S2000: Advanced sequencers for gene detection and panel sequencing.
- IDH1/TERT Gene Assays: Diagnostic assays for glioma.
In addition, Genetron has developed a ctDNA Lung Cancer Assay targeting mutations in the epidermal growth factor receptor gene. The company collaborates with global biopharmaceutical firms to offer tailored genomics research and clinical development services.
Recently, Genetron announced a definitive Agreement and Plan of Merger with New Genetron Holding Limited and Genetron New Co Limited. As part of the merger, Genetron will become a wholly-owned subsidiary of the parent company in a transaction valued at approximately US$126.0 million. This merger signifies a pivotal transformation, taking the company private and enhancing its strategic flexibility.
The merger completion, expected in the first quarter of 2024, is subject to customary closing conditions, including shareholder votes and regulatory approvals. Upon completion, Genetron's American Depositary Shares (ADSs) will be delisted from the Nasdaq Global Market, and the company will terminate its ADS program. The company aims to finalise this transition efficiently to focus on its long-term vision and goals.
For the latest updates and detailed information on Genetron Holdings Limited and its innovative contributions to precision oncology, please visit their Investor Relations page.
ResearchAndMarkets.com has released a new report on the Whole Genome and Exome Sequencing market, forecasting growth from 2023 to 2027. The report includes detailed analyses across 14 countries and 5 regions, emphasizing the rapid decrease in sequencing costs and the explosion of market entrants. It addresses major trends like Direct to Consumer Testing, the implications of genomic sequencing for newborns, and the role of innovative technologies. The report outlines both growth drivers, such as advancements in fertility technology and pathogen testing, and challenges including regulatory hurdles in DTC-WGS.
The Global Companion Diagnostic Markets Report 2023 highlights the increasing role of companion diagnostics in cancer management, particularly in oncology and immune-oncology.
This report provides comprehensive market analysis, covering 18 countries and 4 regions, and is aimed at analysts and planners in the diagnostics and pharmaceutical sectors.
With the FDA's support, this sector is transitioning from laboratory settings to clinical applications, enabling significant business opportunities. The report includes information on market size, growth drivers, and challenges to assist stakeholders in making informed investment decisions.
The new report from ResearchAndMarkets.com forecasts significant growth in the global genetic testing market from 2023 to 2027, driven by advancements in genetic understanding and reduced testing costs. With various applications like newborn screening, oncology, and direct-to-consumer testing, the market is experiencing increased demand. The report provides extensive analysis across 14 countries and covers pivotal technologies such as PCR and NGS. Notably, factors like pharmacogenomics and the rise of personalized medicine are expected to propel market expansion. Companies are urged to leverage this data for informed decision-making.
Research and Markets has released a comprehensive report titled 'Market Forecasts for Immuno-Oncology Diagnostics 2023 to 2027'. This report outlines the transformative potential of immuno-oncology diagnostics in cancer therapy, highlighting growth driven by advancements in histology, genomics, and liquid biopsies. The report details key market trends, including the crucial need for biomarkers to tailor therapies effectively. It covers topics like immune system technology, market definitions, and the global landscape of immuno-oncology diagnostics. The report emphasizes industry developments and profiles leading companies, aiming to provide valuable insights for stakeholders in this evolving field.
The in-vitro diagnostics market in North America is expected to grow at a CAGR of 3.3% from 2022 to 2028, highlighting significant investment opportunities exceeding USD 3 trillion. In 2022, North America held the largest market share at 40% globally, driven by high healthcare expenditure and a patient population with chronic conditions (60%-80%) demanding diagnostic services. The market size is projected to reach USD 127.56 billion by 2028 from USD 105 billion in 2022. The COVID-19 pandemic accelerated the demand for IVD solutions, especially point-of-care diagnostics, emphasizing the growing importance of rapid testing and new product launches.
The Global Immuno-Oncology Diagnostics Market Report 2023-2028 has been released by ResearchAndMarkets.com. The report highlights a rapidly growing segment within diagnostics, fueled by advancements in histology, genomics, and liquid biopsy. This area seeks to enhance cancer therapies by utilizing the body's immune defenses, making biomarkers crucial for effective treatment selection. The market is characterized by intense competition among pharmaceutical and diagnostic companies. Key topics include market definitions, technology trends, and critical developments impacting the industry, suggesting significant growth potential in immuno-oncology diagnostics.
Genetron Holdings Limited (GTH) announced on January 18, 2023, that it has regained compliance with the Nasdaq's Minimum Bid Price Requirement. The company received a Compliance Notice from Nasdaq stating that its American depositary shares (ADSs) closed at or above $1.00 for ten consecutive business days from December 29, 2022, to January 13, 2023. Previously, on October 28, 2022, Genetron was notified of non-compliance after its ADSs fell below the required price for 30 consecutive days. With this recent development, Genetron's compliance status is now resolved.
Genetron Holdings Limited (GTH) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of US$1.00 per share, as its American depositary shares (ADSs) have closed below this threshold for 30 consecutive business days. The Company has a compliance period of 180 days, until April 26, 2023, to regain compliance by maintaining the required bid price. Genetron assures that its operational activities remain unaffected and intends to monitor its ADS price closely during this period.
The global oncology liquid biopsy market is projected to grow to
This market is expected to achieve a CAGR of 46% from 2022 to 2027, indicating significant demand for less invasive diagnostic tools in oncology.
Genetron Holdings Limited (NASDAQ: GTH) reported its Q2 2022 financial results, revealing a 1.9% decrease in total revenue to RMB 137.7 million (US $20.6 million). While LDT revenue grew by 31.8% to RMB 114.9 million, IVD revenue fell sharply, down 78.8% to RMB 9.3 million. The gross profit decreased 40.6%, and the operating loss widened to RMB 170.1 million (US $25.4 million). The company also received CAP accreditation, launched new testing services, and announced a non-binding acquisition offer of US $0.27 per ordinary share, prompting a special committee review.
FAQ
What is the market cap of Genetron Holdings (GTH)?
What does Genetron Holdings Limited specialize in?
What are some of Genetron's key products?
What recent corporate action has Genetron announced?
What is HCCscreen?
What is the significance of Genetron's merger?
What happens to Genetron's ADSs after the merger?
Who are the major stakeholders involved in the merger?
When is the merger expected to complete?
What services does Genetron offer in genomics research?
Where can I find more information about Genetron's financial filings?
